DEPUY SYNTHES SALES, INC. v. TROSPER | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for DEPUY SYNTHES SALES, INC. v. TROSPER

Sort by

Viewing results 1‒6 of 6

Smith & Nephew PLC
Smith & Nephew in talks to buy NuVasive for over $3bn
...Before Alere, Mr Nawana spent more than 15 years at Johnson & Johnson, including time as president of its DePuy Synthes spine business....
February 8, 2019
Pharmaceuticals sector
Johnson & Johnson slips in first quarter
...Pharmaceutical sales were up 10 per cent to $6.8bn, and medical devices and diagnostics up 10 per cent to $7.1bn, much the result of its acquisition of Synthes....
April 16, 2013
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
World
Doctors call for tougher rules on devices
...Consolidation is intensifying, including Johnson & Johnson’s recent $21bn purchase of Synthes of Switzerland....
May 16, 2011
US downturn
J&J first quarter profits slide 23%
...J&J booked $271m of charges related to its DePuy ASR, a hip replacement which had to be recalled....
April 19, 2011
US healthcare reform
Deal could be cure for Johnson & Johnson
...But Synthes has proved to be highly profitable, and last year group sales rose 8.6 per cent to $3.69bn while net profits increased nearly 25 per cent to $908m....
April 18, 2011
FT AlphavilleNeil Hume
Bid or no bid for Smith & Nephew?
...We may also see Smith & Nephew seeking out a white knight approach from Biomet / Synthes or possibly private equity, but it is hard to see how any of these could outbid J&J....
January 10, 2011
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference

Previous pagePage 1 of 1Next page